Показано 0 из 0
Дата |
---|
08.02.2023 |
07.02.2023 |
06.02.2023 |
03.02.2023 |
02.02.2023 |
01.02.2023 |
31.01.2023 |
30.01.2023 |
27.01.2023 |
26.01.2023 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
|
|
2.98
|
2.98
|
2.98
|
2.98
|
|
|
77.00
|
|
|
|
2.86
|
2.50
|
2.98
|
2.98
|
|
|
20 770.00
|
|
|
|
2.36
|
2.36
|
2.94
|
2.86
|
|
|
22 049.00
|
|
|
|
2.54
|
2.48
|
2.54
|
2.48
|
|
|
279.00
|
|
|
|
2.48
|
2.48
|
2.60
|
2.60
|
|
|
10 902.00
|
|
|
|
2.32
|
2.26
|
2.50
|
2.32
|
|
|
15 203.00
|
|
|
|
2.26
|
2.26
|
2.26
|
2.26
|
|
|
|
|
|
|
2.40
|
2.20
|
2.52
|
2.20
|
|
|
9 322.00
|
|
|
|
2.30
|
2.30
|
2.40
|
2.32
|
|
|
27 423.00
|
|
|
|
2.36
|
2.26
|
2.40
|
2.28
|
|
|
29 147.00
|
|
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company’s drugs are intended to provide patients with various treatment options. Its pipeline is protected by a portfolio of patents and comprises three principal drug candidates that are in various stages of development.